Cabozantinib is the active ingredient in two of Exelixis' three approved drugs (Cabometyx and Cometriq) and its strongest US patent covering cabozantinib’s composition of matter expires in 2030.
Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...
This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the ...
When a doctor prescribes a medication for a use other than one that has been approved by the FDA, it’s known as off-label use. Doctors prescribe off-label for several reasons including ...
Off-label means that, when appropriate, a doctor prescribes a drug for a condition or at a dosage that the FDA has not approved. There has been a shortage of Mounjaro since its approval in 2022.